HomeAbout Investor AwarenessClient ServicesClient Success StoriesManagement TeamClient ProfilesContact Us

Client Profiles


BioRestorative TherapiesBioRestorative Therapies, Inc.
BioRestorative Therapies, Inc. (BRTX) develops therapeutic products and medical therapies using cell and tissue protocols, primarily involving adult (non-embryonic) stem cells. The Company has two dynamic Cell-Based Therapeutic Programs: Extraordinary Technology to Treat Chronic Lumbar Disc Disease (Bulging and Herniated Spinal Discs) and Metabolic Disorders (Diabetes); Encouraging Human Data for Disc Program.
Yahoo Data and NewsCompany Web SiteCompany Profile

Yahoo Data and News
 Yahoo Finance Data & News
Company Profile Company Profile (PDF)
Company Web Site Company Web Site

News and Updates

Pressure BioSciences' SCIEX Deal Could Dramatically Accelerate Revenue
REDONDO BEACH, CA / ACCESSWIRE / January 28, 2016 / SCIEX, a global leader in life science analytical technologies, and a wholly-owned subsidiary of Danaher Corporation (NYSE:DHR), recently announced an exclusive co-marketing agreement with Pressure BioSciences, Inc. (PBIO). PBIO is a worldwide leader in the development and sale of pressure cycling technology (PCT)-based sample preparation systems to the life sciences research market. Under the agreement, the companies will jointly promote PBIO's PCT-based sample preparation systems and SCIEX's mass spectrometry equipment, with a focus on improved sample preparation, a crucial step performed by hundreds of thousands of research laboratories worldwide. This combination of technologies could result in superior biological insights and discoveries in the life sciences industry, and in rapid and dramatic revenue growth for PBIO. (full story)

SeeThruEquity Issues Update on Pressure BioSciences (OTCQB: PBIO)
NEW YORK, NY-January 25, 2015- SeeThruEquity, a leading independent equity research and corporate access firm focused on small-cap and micro-cap public companies, today announced it has issued an update on Pressure BioSciences, Inc. (PBIO). (full story)

SCIEX Announces Exclusive Co-Marketing Agreement with Pressure BioSciences, Inc.
FRAMINGHAM, Mass.--January 12, 2016 SCIEX, a global leader in life science analytical technologies, today announced an exclusive co-marketing agreement with Pressure BioSciences, Inc. (PBI) (PBIO), a worldwide leader in the development and sale of high pressure-based sample preparation systems to the life sciences research market. This relationship will uniquely position SCIEX to address a major challenge in complex sample preparation by marketing a complete solution to increase the depth, breadth, and reproducibility of protein extraction, digestion and quantitation in all tissue types, including challenging samples like tumors.
(full story)

More Articles

Upcoming Events

There are no events to display at this time.
Complete Events List

Cleveland BioLabsCleveland BioLabs
Cleveland BioLabs, Inc. is an innovative biopharmaceutical company seeking to develop first-in-class pharmaceuticals designed to address diseases with significant medical need. CBLI’s programs are focused on the use of novel toll-like receptor agonists to activate the immune system for therapeutic benefit. The Company's most advanced product candidate is entolimod, which is being developed as a radiation countermeasure and an immunotherapy for oncology and other indications. The company maintains strategic relationships with the Cleveland Clinic and Roswell Park Cancer Institute.

CBLI is focused on achieving two major objectives:

  1. Commercializing entolimod as a medical radiation countermeasure through pre-Emergency Use Authorization.
  2. Achieving clinical validation and partnerships for cancer immunotherapies and vaccine adjuvant technology.
Yahoo Data and NewsCompany Web Site

CorbusCorbus Pharmaceuticals, Inc.
Corbus Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat life threatening ("orphan") inflammatory-fibrotic diseases with clear unmet needs. The Company’s lead product Resunab is a first- in-class oral anti-inflammatory expected to commence Phase-2a clinical trials for the treatment of cystic fibrosis and scleroderma pending FDA approval of IND.

About Resunab™
Resunab is a novel synthetic oral drug with unique anti-inflammatory and anti-fibrotic activity. Pre-clinical and Phase 1 studies have shown Resunab to have an excellent safety profile in humans and promising potency. Resunab binds to the CB2 receptor of immune cells and triggers a process known as "inflammatory resolution", in effect turning chronic inflammation "off."
Yahoo Data and NewsCompany Web Site

Pressure BioSciences, Inc.Pressure BioSciences, Inc.
Pressure BioSciences, Inc. is a leader in the development and sale of broadly enabling, pressure cycling technology ("PCT")-based sample preparation solutions to the worldwide life sciences industry. The Company develops, markets, and sells proprietary laboratory instrumentation and associated consumables to the estimated $6 billion life sciences sample preparation market. Our products are based on the unique properties of both constant (i.e., static) and alternating (i.e., pressure cycling technology, or PCT) hydrostatic pressure. PCT is a patented enabling technology platform that uses alternating cycles of hydrostatic pressure between ambient and ultra-high levels to safely and reproducibly control bio-molecular interactions. To date, we have installed over 250 PCT systems in approximately 160 sites worldwide. There are over 100 publications citing the advantages of the PCT platform over competitive methods, many from key opinion leaders. Our primary application development and sales efforts are in the biomarker discovery and forensics areas. Customers also use our products in other areas, such as drug discovery & design, bio-therapeutics characterization, soil & plant biology, vaccine development, histology, and forensic applications.
Yahoo Data and NewsCompany Web Site




  Disclaimer     Financial Glossary

©2013 Investor Awareness, Inc. All rights reserved